Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking, in-vitro and molecular dynamics study

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.0c01563 ◽

2021 ◽

Vol 64 (2) ◽

pp. 909-924 ◽

Author(s):

Zhuming Zhang ◽

Peter J. Connolly ◽

Heng Keang Lim ◽

Vineet Pande ◽

Lieven Meerpoel ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Clinical Stage ◽

Wild Type ◽

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

European Urology ◽

10.1016/j.eururo.2016.04.023 ◽

2016 ◽

Vol 70 (6) ◽

pp. 963-970 ◽

Cited By ~ 55

Author(s):

Matthew R. Smith ◽

Emmanuel S. Antonarakis ◽

Charles J. Ryan ◽

William R. Berry ◽

Neal D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

High Risk ◽

Antitumor Activity ◽

Receptor Antagonist ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study

Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line

Medical Science Monitor ◽

10.12659/msm.915828 ◽

2019 ◽

Vol 25 ◽

pp. 4438-4449 ◽

Author(s):

Mengjuan Yuan ◽

Yingying Gao ◽

Luo Li ◽

Wei Sun ◽

Honglin Cheng ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Prostate Cancer Cell ◽

Cancer Cell Line ◽

Prostate Cancer Cell Line ◽

Castration Resistant ◽

Morphogenetic Protein

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Oncotarget ◽

10.18632/oncotarget.8456 ◽

2016 ◽

Vol 7 (18) ◽

pp. 26259-26274 ◽

Cited By ~ 38

Author(s):

Steven Kregel ◽

James L. Chen ◽

Westin Tom ◽

Venkatesh Krishnan ◽

Jacob Kach ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Second Generation ◽

Acquired Resistance ◽

Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.013 ◽

2020 ◽

Vol 134 ◽

pp. 29-40 ◽

Author(s):

Tie Zhou ◽

Weidong Xu ◽

Wei Zhang ◽

Ye Sun ◽

Honghua Yan ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Androgen Receptor ◽

Phase I ◽

Receptor Antagonist ◽

Phase I Clinical Trial ◽

PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration‐resistant prostate cancer by suppressing the wnt3a/β‐catenin pathway

Journal of Cellular Physiology ◽

10.1002/jcp.28195 ◽

2019 ◽

Vol 234 (9) ◽

pp. 15472-15486 ◽

Author(s):

Luo Li ◽

Zhongbo Du ◽

Yingying Gao ◽

Yu Tang ◽

Yanru Fan ◽

...

Keyword(s):

Prostate Cancer ◽

Drug Resistance ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3417-3 ◽

2017 ◽

Vol 80 (6) ◽

pp. 1063-1072 ◽

Cited By ~ 8

Author(s):

Nobuaki Matsubara ◽

Hirofumi Mukai ◽

Ako Hosono ◽

Mai Onomura ◽

Masaoki Sasaki ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Phase 1 ◽

Japanese Patients ◽

Phase 1 Study ◽

Castration Resistant ◽

New Generation

Abstract LB-203: Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer

10.1158/1538-7445.am2008-lb-203 ◽

2008 ◽

Author(s):

Howard I. Scher ◽

Thomasz Beer ◽

Celestia S Higano ◽

Daniel C Danila ◽

Julia Shelkey ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Phase I ◽

Receptor Antagonist ◽

Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1

International Journal of Oncology ◽

10.3892/ijo.2019.4774 ◽

2019 ◽

Cited By ~ 3

Author(s):

Yingying Gao ◽

Luo Li ◽

Ting Li ◽

Lei Ma ◽

Mengjuan Yuan ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Cancer Metastasis ◽

Caveolin 1 ◽

Castration Resistant ◽

Prostate Cancer Metastasis

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3433-3 ◽

2017 ◽

Vol 80 (6) ◽

pp. 1073-1077 ◽

Author(s):

Nobuaki Matsubara ◽

Hirofumi Mukai ◽

Ako Hosono ◽

Mai Onomura ◽

Masaoki Sasaki ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Receptor Antagonist ◽

Phase 1 ◽

Japanese Patients ◽

Phase 1 Study ◽

Castration Resistant ◽

New Generation